Literature DB >> 12754737

Analysis of genetic alterations, classified according to their DNA ploidy pattern, in the progression of colorectal adenomas and early colorectal carcinomas.

Tamostu Sugai1, Hiroshi Takahashi, Wataru Habano, Shin-ichi Nakamura, Kimihiko Sato, Seishi Orii, Kazuyuki Suzuki.   

Abstract

DNA aneuploidy is a biological marker of the oncogenic potential of colorectal adenomas. The accumulation of genetic alterations of cancer-related genes is also essential for colorectal carcinogenesis. However, it is unclear whether there is any relationship between these genetic alterations and the DNA ploidy of colon tumour cells in the progression of colorectal adenomas and early colorectal carcinomas. Here we have studied the DNA ploidy state and genetic alterations occurring in colorectal tumours using the crypt isolation technique. Crypts isolated from a total of 106 colorectal tumors (adenoma, 93; early carcinoma, 13) were examined using a combination of flow cytometric analysis of DNA content, polymerase chain reaction-microsatellite assay, and single-strand conformation polymorphism assay for evidence of chromosomal allelic imbalance (AI; 17p; 5q; 18q) or p53 gene mutation. In addition, we examined microsatellite instability (MSI) with BAT 26 primer sets. DNA multiploidy was infrequently detected in colorectal adenomas (15.1%), in contrast to early carcinomas (46.2%). There was a significant difference in the incidence of AI of chromosome 18q between diploid adenomas and aneuploid populations of multiploid adenomas (18.1% vs 57.1%, p = 0.0043). Mutation of p53 was also found more frequently in aneuploid populations of early multiploid colorectal carcinomas than in early diploid colorectal carcinomas (66.7% vs 0%, p = 0.021). MSI was found in only 2 of 93 adenomas, with no MSI detected in early colorectal cancers. The two MSI-positive adenomas were diploid. We subdivided multiploid adenomas into two groups: those with a low or a high DNA index (DI). The incidence of genetic alterations of high-DI adenomas did not differ from those of low-DI adenomas. Allelic imbalance involving loci on chromosome 18q and mutations of p53 seems to be associated with the progression of diploidy to multiploidy in colorectal tumours. On the other hand, MSI may be associated with the development of some diploid tumours. In addition, the incidence of genetic alterations in the colorectal adenomas that we examined appears to be independent of the tumour's DNA index. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12754737     DOI: 10.1002/path.1340

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  11 in total

1.  Aneuploidy arises at early stages of Apc-driven intestinal tumorigenesis and pinpoints conserved chromosomal loci of allelic imbalance between mouse and human.

Authors:  Paola Alberici; Emma de Pater; Joana Cardoso; Mieke Bevelander; Lia Molenaar; Jos Jonkers; Riccardo Fodde
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

2.  Analysis of molecular alterations in left- and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis: proposal for new molecular profile of colorectal carcinomas.

Authors:  Tamotsu Sugai; Wataru Habano; Yu-Fei Jiao; Mitsunori Tsukahara; Yuichiro Takeda; Koki Otsuka; Shin-ichi Nakamura
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

3.  Array CGH identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal- and microsatellite-unstable sporadic colorectal carcinomas.

Authors:  Silke Lassmann; Roland Weis; Frank Makowiec; Jasmine Roth; Mihai Danciu; Ulrich Hopt; Martin Werner
Journal:  J Mol Med (Berl)       Date:  2006-12-02       Impact factor: 4.599

4.  Multiple biomarkers of colorectal tumor in a differential diagnosis model: a quantitative study.

Authors:  Wen Jin; Mei-Qin Gao; Zhi-Wu Lin; Dai-Xing Yang
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

5.  Genome-wide copy neutral LOH is infrequent in familial and sporadic microsatellite unstable carcinomas.

Authors:  Marjo van Puijenbroek; Anneke Middeldorp; Carli M J Tops; Ronald van Eijk; Heleen M van der Klift; Hans F A Vasen; Juul Th Wijnen; Frederik J Hes; Jan Oosting; Tom van Wezel; Hans Morreau
Journal:  Fam Cancer       Date:  2008-04-15       Impact factor: 2.375

6.  The application of methylation specific electrophoresis (MSE) to DNA methylation analysis of the 5' CpG island of mucin in cancer cells.

Authors:  Seiya Yokoyama; Sho Kitamoto; Norishige Yamada; Izumi Houjou; Tamotsu Sugai; Shin-ichi Nakamura; Yoshifumi Arisaka; Kyoichi Takaori; Michiyo Higashi; Suguru Yonezawa
Journal:  BMC Cancer       Date:  2012-02-14       Impact factor: 4.430

7.  Hydrophobic bile acids, genomic instability, Darwinian selection, and colon carcinogenesis.

Authors:  Claire M Payne; Carol Bernstein; Katerina Dvorak; Harris Bernstein
Journal:  Clin Exp Gastroenterol       Date:  2008-12-16

8.  Genomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy: an exploratory study.

Authors:  Chiara Molinari; Michela Ballardini; Nazario Teodorani; Massimo Giannini; Wainer Zoli; Ermanno Emiliani; Enrico Lucci; Alessandro Passardi; Paola Rosetti; Luca Saragoni; Massimo Guidoboni; Dino Amadori; Daniele Calistri
Journal:  Radiat Oncol       Date:  2011-11-18       Impact factor: 3.481

9.  ∆ DNMT3B4-del Contributes to Aberrant DNA Methylation Patterns in Lung Tumorigenesis.

Authors:  Mark Z Ma; Ruxian Lin; José Carrillo; Manisha Bhutani; Ashutosh Pathak; Hening Ren; Yaokun Li; Jiuzhou Song; Li Mao
Journal:  EBioMedicine       Date:  2015-09-07       Impact factor: 8.143

10.  Molecular subtypes of colorectal cancers determined by PCR-based analysis.

Authors:  Tamotsu Sugai; Makoto Eizuka; Yayoi Takahashi; Tomoyuki Fukagawa; Wataru Habano; Eiichiro Yamamoto; Risaburo Akasaka; Kouki Otuska; Takayuki Matsumoto; Hiromu Suzuki
Journal:  Cancer Sci       Date:  2017-03       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.